Regeneron Pharmaceuticals, Inc. (REGN) earnings: date, estimates, results and stock reactions
Next earnings: Q4 FY2026 on 2027-01-28 (expected, before the open). EPS estimate 25.80, revenue estimate 5.85B.
Over the last 12 reports the stock moved 6.2% on average (either way), rising 8 times and falling 4. EPS beat estimates 10 of 12 times; revenue 10 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-10-30 | 20.07 | 16.51 | +21.6% | 5.12B | 4.58B | +17.4% |
| Q2 FY2026 | 2026-07-30 | 14.29 | 10.16 | +40.6% | 4.29B | 3.82B | +9.7% |
| Q1 FY2026 | 2026-04-29 | 9.47 | 8.91 | +6.3% | 3.61B | 3.48B | -3.4% |
| Q4 FY2025 | 2026-01-30 | 11.44 | 10.74 | +6.5% | 3.88B | 3.81B | +0.7% |
| Q3 FY2025 | 2025-10-28 | 11.83 | 9.65 | +22.6% | 3.75B | 3.59B | +11.5% |
| Q2 FY2025 | 2025-08-01 | 12.89 | 8.43 | +52.9% | 3.68B | 3.29B | +4.8% |
| Q1 FY2025 | 2025-04-29 | 8.22 | 8.62 | -4.6% | 3.03B | 3.25B | -2.0% |
| Q4 FY2024 | 2025-02-04 | 12.07 | 11.21 | +7.7% | 3.79B | 3.74B | +7.5% |